HeteroLink is an autonomous AI agent that watches global pharmaceutical research around the clock — so you can focus on synthesis, not surveillance.
The average pharmaceutical researcher faces thousands of new papers, patents, and compound disclosures every month. The gaps that matter — the synthesis paths not taken, the structures overlooked, the collaborations waiting to be found — get buried.
Scans PubChem, ResearchGate, patent databases, and major journals every day. Filters for your specific compound classes — heterocyclics, sulfonamides, Schiff bases — and flags what's new.
Every morning: a curated briefing of what mattered in your space. New compounds synthesized. Patents filed. Gaps in the literature where you could publish. Collaboration opportunities you didn't know existed.
When a new compound in your space appears, HeteroLink maps it against your existing work — identifying synthetic paths you haven't tried, biological targets you haven't explored, and structural analogues worth investigating.
Flags when researchers at other institutions are working in adjacent spaces — potential co-authors, compounding projects, or licensing opportunities. No more missed connections.
The major AI drug discovery platforms — Insilico, Recursion, Schrödinger — are built for big pharma. Annual contracts in the hundreds of thousands. Research teams at universities and smaller pharmaceutical companies have zero access.
HeteroLink was designed specifically for that gap. An individual researcher in Erbil, Cairo, Karachi, or São Paulo should have the same research intelligence as a team at Pfizer.
Not a general science monitor. Built for pharmaceutical chemistry — heterocyclics, sulfonamides, Schiff bases, metal complexes. Every model is trained on your literature.
Q&A chatbots wait for you to ask. HeteroLink works while you're sleeping — actively scanning, filtering, and alerting. The difference between a research assistant and a research employee.
No enterprise contracts. No team minimums. A researcher with a laptop should be able to afford the same intelligence as a $10B biotech. That's the world we're building toward.
HeteroLink will find it before you do — and tell you exactly what it means for your work.